UNSPSC 51142009: Metamizol or metamizole

This classification denotes an anti-inflammatory agents, non-steroidal, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VSU62Z74ON. European Medicines Agency schedules Metamizole sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08810MIG. Metamizole sodium generally arises in the molecular formula C13H16N3O4S.NA. The term METAMIZOLE SODIUM is an International Non-Proprietary Name or INN. SMILES: CC1=C(C(=O)N(N1C)C2=CC=CC=C2)N(C)CS(=O)(=O)O.

UNSPSC 51142009 Metamizol or metamizole is a Commodity code that nominally addresses a specific analgesic and anti-inflammatory pharmaceutical. Recent state and local solicitations tagged with this code do not reflect metamizol procurement; instead, they span naloxone (opioid-overdose reversal), safe drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products through cooperative purchasing. The code shows little relevant recent activity aligned with its stated scope. The issuing bodies include Seminole County, Florida (a county health procurement), the Texas Health and Human Services Commission (a state agency), and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), which serves multiple states and local governments. The geographic spread spans Florida, Texas, and Minnesota, with MMCAP extending into Oregon.

Representative recent opportunities illustrate the mismatch between code and actual procurement. Seminole County issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, with responses due July 26, 2023. Texas HHS posted RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and wholesaler arrangements. Minnesota's MMCAP released RFP S1070000015802 in January 2026 with a March 26, 2026 response deadline for generic multi-source pharmaceuticals and OTC products supplied through three authorized wholesalers, with contract awards effective July 1, 2026. Vendors must meet cGMP and DSCSA compliance, maintain relationships with at least two authorized wholesalers, and accept a 3 percent administrative fee. The code does not support a focused pursuit strategy for metamizol-specific pharmaceutical products.